Compare Novo Nordisk A/S (NVO) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ProShares Ultra QQQ ETF — how do they compare? Novo Nordisk A/S trades at $45.04 (market cap $198.57B), while ProShares Ultra QQQ ETF trades at $89.45. The key difference: Novo Nordisk A/S pays a 4.03% dividend while ProShares Ultra QQQ ETF pays none, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | QLD | |
|---|---|---|
Market Cap | $198.57B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $100.53 |
52-Week Low | $35.29 | $57.16 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
QLD trades at $90.53, down 0.17% on the day. The technical outlook is bullish, with moving averages signaling strength and support at $90. Recent news highlights institutional buying, with 180 Wealth Advisors increasing its stake by 29.4% in Q2 2026. The ETF has delivered over 10,000% total return since inception, demonstrating long-term compounding power.
Outlook remains positive for investors seeking leveraged Nasdaq-100 exposure, but risks include daily rebalancing decay and market volatility. The ETF suits tactical allocations given its bullish technicals and institutional interest, though it requires active risk management due to its leveraged structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
